Meta Pixel

News and Announcements

Heyrex Limited – CEO Interview

  • Published April 24, 2014 2:09PM UTC
  • Publisher Wholesale Investor
  • Categories Executive Interviews

Heyrex Limited is a New Zealand data and technology company that provides a unique activity, wellness and productivity monitoring service for animals.

Heyrex is a valuable tool for the management of animal assets, care of companion animals, generation of new revenue streams for service providers and peace of mind to animal care givers.

Heyrex is used by veterinary professionals, farmers and researchers to manage and monitor animal productivity, health, behaviour, treatments and general wellbeing for production and companion animals.

Heyrex collects data via its proprietary monitors via a cloud-based service that enables Heyrex to notify clients of important changes in productivity, wellness and build valuable industry data. Heyrex is priced attractively (SaaS model) to ensure affordability for large scale monitoring and provides revenue generation opportunities to its clients.

Heyrex is a turn-around business opportunity that is now launching its products internationally, targeting specifically the US, European and key Asian markets and is seeking equity investment to accelerate its global growth.

Please listen to Nathan Lawrence, CEO.

Capital Insights
What is a Wholesale Investor in Australia? Complete 2026 Guide

What is a Wholesale Investor in Australia? A wholesale investor is an individual or entity that meets specific financial thresholds set out in the Corporations Act 2001 (Cth), qualifying them to access investment opportunities that are not available to general retail investors. These include private equity rounds, venture capital deals, pre-IPO placements, alternative funds, and […]

Capital Insights
Why the 20-Year Hold Is the Secret to Australian Life Sciences Returns

Australia represents 0.3% of the world’s population. Yet it generates more than 3% of global research output. Cochlear implants. Wi-Fi. The HPV vaccine. These are not statistical anomalies. They are proof points of a structural advantage that Australia has failed to capitalise on. The country has a world-class research base. But it watches companies scale […]

Join over 45,000+ sophisticated investors

Join Now